Multiple Myeloma & CAR-T Cell Therapy
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Meet the Speakers

      Saad Usmani, MD, MBA, FACP

      Hematologic Oncologist
      Chief, Myeloma Service

      Memorial Sloan Kettering Cancer Center

      Krina Patel, MD, MSc

      Associate Professor
      Department of Lymphoma/Myeloma

      The University of Texas MD Anderson Cancer Center

      Peter Voorhees, MD

      Professor of Medicine

      Chief, Plasma Cell Disorders Division

      Vice Chair for Administration and Clinical Care

      Associate Medical Director of Clinical Trials

      Department of Hematologic Oncology and Blood Disorders

      Levine Cancer Institute, Atrium Health/Wake Forest Baptist

      Program Objectives

      Explore multiple myeloma and CAR-T cell therapy

      Describe unmet needs in the treatment of patients with relapsed/refractory multiple myeloma

      Review CAR-T cell therapy administration and recommendation for the management of AEs

      AE, adverse events; CAR-T, chimeric antigen receptor-T cell.
      © Janssen Biotech, Inc. 2024 08/24 cp-467365v1